Business Wire

Q4-INC.

Share
Q4 Inc. Announces TSX Acceptance of Normal Course Issuer Bid

Q4 Inc. (TSX:QFOR), a leading capital markets communications platform, announced today that the Toronto Stock Exchange (the “TSX”) has accepted the Company’s notice of intention to conduct a normal course issuer bid (“NCIB”).

Under the NCIB program, the Company is authorized to purchase up to 2,519,889 of its common shares, which represents 10% of the public float as of March 15, 2022. As of March 15, 2022, the Company had 39,625,596 common shares issued and outstanding and a public float of 25,198,894 common shares. Purchases will be made through normal course purchases effected through the facilities of the TSX and/or alternative Canadian trading systems, or such other means as may be permitted by the Ontario Securities Commission or Canadian Securities Administrators. Pursuant to the NCIB, the Company may acquire, from time to time, up to 10,421 common shares per day (which is equal to 25% of 41,685 common shares, being the average daily trading volume for the Company’s common shares for the period ended February 28, 2022), subject to certain exceptions, including block purchase exceptions. All shares purchased by the Company under the NCIB will be cancelled. Purchases may commence on March 25, 2022 and will conclude on the earlier of the date on which the Company has purchased the maximum number of common shares under the NCIB and March 24, 2023.

In deciding to establish the NCIB, the Company believes that the market price of the common shares may not adequately reflect their value and that current market conditions provide opportunities for the Company to acquire common shares at attractive prices. In the Company’s view, having the option to opportunistically repurchase common shares could be an effective use of its cash resources and could be in the best interests of the Company and its shareholders. It would both enhance liquidity for shareholders seeking to sell, and provide an increase in the proportionate interests of shareholders wishing to maintain their positions.

Purchases will be made by the Company in accordance with the requirements of the TSX and the price which the Company will pay for any such common shares will be the market price of any such common shares at the time of acquisition, or such other price as may be permitted by the TSX.

In connection with the NCIB program, the Company has entered into an automatic repurchase plan with its designated broker to allow for purchases of its common shares during certain pre-determined black-out periods, subject to certain parameters as to price and number of shares. Outside of these pre-determined black-out periods, shares will be repurchased in accordance with management’s discretion, subject to applicable law.

About Q4 Inc.

Q4 Inc. (TSX: QFOR) is a leading capital markets communications platform that is transforming the way publicly traded companies, investors and investment banks make decisions to efficiently discover, communicate and engage with each other. The Q4 end-to-end technology platform facilitates interactions across the capital markets through its IR website products, virtual events solutions, capital markets CRM, shareholder and market analytics tools. The firm is a trusted partner to more than 2,600 public companies globally including many of the most respected brands in the world. Q4 is based in Toronto, with offices in New York and London. Learn more at q4inc.com .

Caution Concerning Forward-Looking Information

This news release contains forward-looking information within the meaning of applicable securities legislation. Forward-looking information generally can be identified by the use of forward-looking words such as “expect”, “continue”, “anticipate”, “intend”, “aim”, “plan”, “believe”, “budget”, “estimate”, “forecast”, “foresee”, “close to”, “target” or negative versions thereof and similar expressions. Some of the specific forward-looking information in this news release includes, among other things, statements regarding future purchases of common shares under the Company’s NCIB program. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to, those that are disclosed in the Company’s most recent annual information form. All forward-looking information in this news release speaks as of the date of this news release. The Company does not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise except as required by law. Additional information about these assumptions and risks and uncertainties is contained in the Company’s filings with securities regulators, including its latest annual information form and Management’s Discussion and Analysis. These filings are also available at the Company’s website at q4inc.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Brenus Pharma Expands Its Global Scientific Advisory Board With Us Immuno-Oncology Expert Prof. Olivera J. Finn12.11.2025 19:00:00 CET | Press release

Brenus Pharma, a clinical-stage biotechnology company developing first-in-class in vivo immunotherapies for solid tumors, announced the appointment of Olivera J. Finn, Distinguished Professor at the University of Pittsburgh School of Medicine, to its Scientific Advisory Board (SAB). This strategic addition strengthens Brenus’ international SAB as the company advances its proprietary Stimulated Ghost Cell (SGC) platform and lead candidate STC-1010 toward its next clinical milestones. Globally recognized for her groundbreaking contributions to cancer immunology, Prof. Finn has led major discoveries in tumor antigens. She identified the MUC1 tumor antigen, a cornerstone in cancer research, and discovered cyclin B1 as a promising target for anti-cancer immunotherapy. Over her career, she has authored more than 220 peer-reviewed publications and co-led extensive clinical trials across pancreatic, colon, breast, prostate, and lung cancers. She also served as President of the American Associa

Telcoin Makes U.S. Banking History with Approval to Launch the First Regulated Digital Asset Bank12.11.2025 19:00:00 CET | Press release

Charter approval allows Telcoin Digital Asset Bank to establish a bridge between traditional banking and decentralized finance, including the creation of eUSD as the nation’s first bank-issued stablecoin. Telcoin today announced its final charter approval from the Nebraska Department of Banking and Finance to launch Telcoin Digital Asset Bank, the first Digital Asset Depository Institution in the United States. The charter positions Telcoin to become the first true blockchain bank, directly connecting U.S. bank accounts to regulated “Digital Cash” stablecoins. Its flagship product, eUSD, will be the first bank-issued, on-chain U.S. dollar stablecoin, offering consumers and businesses a secure, compliant way to use Digital Cash for payments, remittances, and savings. Notably, it is also the first bank charter to explicitly authorize connecting U.S. consumers to DeFi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112119122

Mindbreeze Named a Leader in the IDC MarketScape: Worldwide General-Purpose Knowledge Discovery Software 2025 Vendor Assessment12.11.2025 18:01:00 CET | Press release

Mindbreeze, a leading global provider of AI-based knowledge management solutions, has been named a Leader in the IDC MarketScape: Worldwide General-Purpose Knowledge Discovery Software 2025 Vendor Assessment (doc #US53011225, November 2025). In the IDC MarketScape 14 vendors of knowledge discovery software were evaluated. For the assessment, IDC divided potential key measures for success into two primary categories: capabilities and strategies. Get your complimentary copy of the excerpt here. The IDC MarketScape notes, “Companies looking for reliable, context-aware insights from internal and external sources should consider Mindbreeze. The platform enables decision making for compliance, risk management, and strategic planning, appealing to business areas such as customer service, finance, legal, and HR. It can tailor pre-built search applications to specific departments for search while supporting broader knowledge management and digital workspace initiatives.” "We are proud to be rec

Ardian Set to Mobilize Development Finance Institutions (DFIs) With European Investment Bank (EIB), Proparco and British International Investment (BII) for a €100m Commitment for Its Nature-Based Solutions Strategy12.11.2025 17:12:00 CET | Press release

Ardian’s Nature-Based Solutions strategy is dedicated to investing in projects in reforestation, wetlands and mangrove restoration intended to protect biodiversity. The strategy aims at providing carbon credit to corporates in their decarbonisation strategy. It will enable the sequestration of 85 million tons of carbon from the atmosphere over a 40 year’ period. European Investment Bank commits €50m and Proparco €20m and British International Investment intend to commit €10m, reflecting increasing DFIs appetite in the sector. Ardian, a world-leading private investment firm, today announces that it has secured commitment from several Development Finance Institutions (DFIs), the European Investment Bank (EIB) and Proparco. British International Investment (BII) have signaled their intention to provide commitment to the Nature Based Solutions fund. Total fund commitments will stand for a total of c. €100m by year end to Ardian’s Nature-Based Solutions (NBS) strategy. As anchor investors,

ViTAA Medical Secures FDA 510(k) Clearance for AiORTA™ Plan — Marking the First Step in Its Hyper-Precise Aortic Care Platform12.11.2025 16:00:00 CET | Press release

FDA clearance marks a pivotal milestone in ViTAA’s broader AiORTA™ suite, designed to support physicians across the full continuum of aortic care ViTAA Medical Solutions Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for AiORTA™ Plan, the company’s fully automated, hyper-precise aortic surgery planning solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112394413/en/ This clearance represents a key milestone in the evolution of ViTAA’s broader AiORTA™ platform, built to support physicians across the full continuum of aortic care. ViTAA’s additional innovations—AiORTA™ Maps and AiORTA™ Watch—are currently in multicenter clinical studies, progressing rapidly toward future clinical release. A Leap Forward in Aortic Surgery Planning Built to automate key preoperative measurements and streamline aortic case prep, AiORTA™ Plan generates a complete aortic plan in minutes.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye